Overview

Price chart · mood · technical indicators

KALA

Kala Pharmaceuticals Incstock Healthcare

Biotechnology

$0.1196.87%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$0.10$20.60

Current: $0.11

Market Comparison

vs Healthcare Sector & Biotechnology Industry

KALA

-96.87%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-3.310.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$101.3MMicro cap

Valuation

Forward P/E: —
PEG ratio: 0.00
P/B: 14.48
P/S (TTM): 23.75
EV/EBITDA: -0.16

Profitability & growth

ROE (TTM): -279.2%
Operating margin: 0.0%
Revenue growth YoY: -100.0%
Dividend yield: —
Beta: -2.24

Last earnings

Mar 31, 2026 · Reported $0.02

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Kala Pharmaceuticals Inc

Company profile

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$101.3M

Shares outstanding$929.5M

52W high$20.60

52W low$0.10

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

KALA

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

KALA SEC Filings - Kala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms

Kala says its private AI research agent is now live for biotech clients

KALA SEC Filings - Kala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms

If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA)

Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA)

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Kala Bio Launches a Revolution for Biotech- First AI Agent

Biotech data stays in-house as KALA BIO bets on on-prem AI for drug R&D

KALA Financials: Income Statement, Balance Sheet & Cash Flow

Kala Pharmaceuticals stock soars after settling $10.6M debt with Oxford Finance

Kala Pharmaceuticals stock soars after settling $10.6M debt with Oxford Finance

Kala Pharmaceuticals stock soars after settling $10.6M debt with Oxford Finance

How a $2 million payment wiped out $10.6 million in company debt

Why Did KALA BIO Shares Jump Over 22% After Hours?

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Kala Pharmaceuticals stock falls after $10 million share offering

KALA BIO Announces Closing of $10 Million Registered Direct

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

KALA BIO (NASDAQ: KALA) prices $10M registered direct sale of 10M shares at $1.00

KALA BIO (NASDAQ: KALA) inks $6M securities deal, appoints David Lazar CEO and chair

About Kala Pharmaceuticals Inc

Classification

Company profile

KALA

Market Comparison

KALA Market Analysis

Overview

KALA

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

KALA SEC Filings - Kala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms

Kala says its private AI research agent is now live for biotech clients

KALA SEC Filings - Kala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms

If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA)

Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA)

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Kala Bio Launches a Revolution for Biotech- First AI Agent

Biotech data stays in-house as KALA BIO bets on on-prem AI for drug R&D

KALA Financials: Income Statement, Balance Sheet & Cash Flow

Kala Pharmaceuticals stock soars after settling $10.6M debt with Oxford Finance

Kala Pharmaceuticals stock soars after settling $10.6M debt with Oxford Finance

Kala Pharmaceuticals stock soars after settling $10.6M debt with Oxford Finance

How a $2 million payment wiped out $10.6 million in company debt

Why Did KALA BIO Shares Jump Over 22% After Hours?

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Kala Pharmaceuticals stock falls after $10 million share offering

KALA BIO Announces Closing of $10 Million Registered Direct

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

KALA BIO (NASDAQ: KALA) prices $10M registered direct sale of 10M shares at $1.00

KALA BIO (NASDAQ: KALA) inks $6M securities deal, appoints David Lazar CEO and chair

About Kala Pharmaceuticals Inc

Classification

Company profile

KALA

Market Comparison